Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bright light, better nights? a trial tests whether tailored lighting can ease sleep troubles and depression in Alzheimer's.

NCT ID NCT01816152

Symptom relief Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial investigates whether daily exposure to a bluish-white light (at least 300-500 lux for two hours) can improve sleep efficiency, reduce depression, and calm agitation in people with mild to moderate Alzheimer's or related dementias. Participants are assigned to one of three light levels, including a dim yellowish-white comparison. The study measures changes in sleep quality, agitation, and depression scores after four weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tailored bluish-white light therapy delivering at least 300-500 lux at the eye for 2+ hours daily
What this could lead to
If it works, this could point toward a simple, drug-free way to improve sleep and mood in people with dementia.
What could go wrong
This is an early-phase trial testing methodology, not yet a proven treatment. The effect may be small or not work for everyone, and the light setup may be impractical for some caregivers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

44 people

The number who actually took part.

Started

Jan 2020

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * mild to moderate Alzheimer's disease and related dementia (ADRD) Exclusion Criteria: * major organ failure, * major illness, * history of head injury, * hypertension or diabetes, * use psychotropic (sleep aid) medicine, obstructing cataracts, macular degeneration, and blindness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia Depression depressive disorder Parasomnias Psychomotor Agitation sleep disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression Sleep disturbances

Contacts and locations

Locations

  • Icahn School of Medicine at Mount Sinai

    Albany, New York, 12204, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.